Hi, Showcasing Three DTx Products Including 'Alzguard' at CES

Participants are gathered around the booth of Hai, a digital therapeutics (DTx) company, set up at CES 2023 held in Las Vegas, USA. (Photo by Hai)

[Asia Economy Reporter Chunhee Lee] Digital therapeutics (DTx) company Hi announced on the 9th that it participated in CES 2023, the world's largest electronics and IT exhibition held in Las Vegas, USA from the 5th to the 8th, showcasing three types of DTx products including 'Alzguard' for screening mild cognitive impairment (MCI).

At this CES, Hi set up a solo booth in the Digital Health section inside the Las Vegas Convention Center (LVCC), rather than the Korean Pavilion in Eureka Park, which is usually for startups. In addition to Alzguard, Hi introduced the anxiety and depression DTx 'Engzirex' and the post-stroke aphasia treatment 'Strokecare' at this CES.

Alzguard is a product that screens early dementia through digital biomarkers such as eye tracking, voice, and cognitive tests. In June last year, at Bio International Convention 2022 (Bio USA), the world's largest pharmaceutical and bio expo held in San Diego, USA, CEO Jinwoo Kim had the opportunity to introduce the product to overseas markets through the Company Presentation program. At that event, questions regarding global expansion followed, including inquiries about clinical trials aimed at overseas markets, approval application status in the US and China, and whether clinical trials are being conducted on races other than Koreans.

Kim Jin-woo, CEO of Hi, is giving a corporate presentation at the Bio International Convention 2022 (BioUSA). / San Diego Photo by Lee Chun-hee

Joonyeop Jung, CTO of Hi, said, “We were surprised by the interest many companies and industry officials showed in Hi’s products at CES,” adding, “Through this event, we were able to reaffirm the excellence of Korean digital healthcare technology.”

Hi plans to accelerate its global expansion following its participation in CES 2023. The global version of Alzguard is scheduled for release in the first half of this year, and Strokecare, developed through joint research with the University of Florida supported by multiple government ministries, is expected to enter clinical trials in the US within the year. Additionally, Hi is preparing to establish a corporation in the US within this month. Feasibility studies and preparations for establishment have been underway since last year, and the team including the CEO has been assembled.

Jinwoo Kim, CEO of Hi, said, “Since Bio USA last year, we have been actively pursuing the establishment of a US corporation. We consider the global expansion of domestic DTx companies as an inevitable destiny, and we believe that growing into a global company is not a mere fantasy. Since the first half of last year, Hi has been preparing for entry into the US market through organizational restructuring, talent acquisition, and strengthening the product lineup,” adding, “CES 2023 was a great opportunity to analyze overseas participants’ reactions in real time before our global expansion.”

This content was produced with the assistance of AI translation services.